Intellia Therapeutics Inc (NTLA) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.41x
Intellia Therapeutics Inc (NTLA) has a Cash Flow-to-Debt Ratio of -0.41x as of December 2025, meaning its operating cash flow of $-69.28 Million could theoretically repay 0% of its total liabilities ($170.73 Million) in one year. See NTLA financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.41x
Operating CF / Total Liabilities
Operating Cash Flow
$-69.28 Million
USD
Total Liabilities
$170.73 Million
USD
Data as of
Dec 2025
Most recent filing
Intellia Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Intellia Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see Intellia Therapeutics Inc (NTLA) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Intellia Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Intellia Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.04x | $-348.88 Million | $170.73 Million | ▼ -86.9% |
| 2024 | -1.09x | $-348.88 Million | $319.06 Million | ▲ +30.4% |
| 2023 | -1.57x | $-394.09 Million | $250.81 Million | ▼ -34.1% |
| 2022 | -1.17x | $-333.29 Million | $284.53 Million | ▼ -32.3% |
| 2021 | -0.89x | $-225.03 Million | $254.22 Million | ▼ -164.7% |
| 2020 | -0.33x | $-49.91 Million | $149.25 Million | ▲ +79.1% |
| 2019 | -1.60x | $-103.24 Million | $64.40 Million | ▼ -81.6% |
| 2018 | -0.88x | $-61.26 Million | $69.39 Million | ▼ -2.3% |
| 2017 | -0.86x | $-65.28 Million | $75.64 Million | ▼ -313.0% |
| 2016 | 0.41x | $36.11 Million | $89.13 Million | ▲ +439.7% |
| 2015 | -0.12x | $-1.76 Million | $14.78 Million | ▲ +89.3% |
| 2014 | -1.11x | $-3.48 Million | $3.13 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.